29940-88-3

Upstream product

• 74-90-8 hydrogen cyanide 
• 29940-86-1 N-(tert-butyl)-3-phenylprop-2-en-1-imine 
• 41175-39-7 4-hydroxy-2-phenyl-butanenitrile 
• 5292-53-5 diethyl benzalmalonate 
• 14025-83-3 3-cyano-3-phenylpropanoic acid ethyl ester 
• 104-55-2 3-phenyl-propenal 

Downstream Products

• 1283569-00-5 C₂₃H₃₁N₅ 
• 1262786-54-8 4-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutanenitrile 
• 1262786-64-0 4-{3-[2-methyl-5-(1-methylethyl)-1H-imidazol-1-yl]-8-azabicyclo[3.2.1]oct-8-yl}-2-phenyl-1-butanenitrile 
• 1262786-40-2 N-(4-{(1R,5S)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-2-phenylbutyl)benzenesulfonamide 
• 1262786-22-0 N-methyl-N-{4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}benzenesulfonamide 
• 1283568-97-7 C₂₉H₃₉N₅O₂S 
• 1262786-38-8 C₃₀H₄₃F₂N₅O 
• 1283568-98-8 C₃₀H₄₃F₂N₅O 
• 1262786-41-3 C₂₈H₃₉F₂N₅O 
• 1282658-13-2 C₃₀H₃₉N₅O 
• 1262786-21-9 C₃₁H₃₆N₄O₂S 
• 1262786-55-9 4-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenyl-1-butanamine 
• 1262786-26-4 3-[({4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}amino)sulfonyl]benzamide 
• 1282657-94-6 C₃₃H₄₂F₂N₄O 

Relevant academic research and scientific papers

Therapeutic compounds: Patent evaluation of WO2011011652A1

A series of sulfonamide derivatives, incorporating azabicyclo[3.2.1]octane and phenyl-propyl scaffolds, were prepared by a succession of original steps. The compounds are claimed to act as antagonists of the C-C chemokine receptor 5 (CCR5) involved in the

THERAPEUTIC COMPOUNDS

The present invention relates to compounds of Formula (I) and (Ia) useful in the treatment of CCR5-related diseases and disorders, for example, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficien

Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1

We describe the synthesis and potency of a novel series of N-substituted 2-phenyl- and 2-methyl-2-phenyl-1,4-diaminobutane- based CCR5 antagonists. Compounds 7a and 12f were found to be potent in anti-HIV assays and bioavailable in the low-dose rat PK model.

1-Phenylalkylpiperazines

Described are novel 1-phenylalkylpiperazines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment o

1-PHENYLALKYL-PIPERAZINES

Compounds of formula (I) (R and R1 are a wide range of substituents, Q is CO, CHOH or CHOR2, R2 is alkyl, alkenyl, alkynyl or cycloalkyl group, each of which is optionally substituted, or is alkanoyl, alkanoyoxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminothiocarbonyl, alkylaminothiocarbonyl or dialkylaminothiocarbonyl, R3 is H, alkyl, -alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, each of which is optionally substituted, n is 1 or 2, A is a bond or a methylene or ethylene group and R4 is an aryl or heteroaryl group, either of which is optionally substituted) have affinity for serotoninergic receptors. These compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor activity.